Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2006 1
2007 1
2011 1
2012 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.
Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Kurosawa R, Kawano Y, Yokota S, Sugiyama N, Yuasa H, Fletcher T, Wajdula JS. Mori M, et al. Among authors: wajdula js. Mod Rheumatol. 2011 Dec;21(6):572-8. doi: 10.1007/s10165-011-0450-7. Epub 2011 Apr 11. Mod Rheumatol. 2011. PMID: 21479889
Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S; Etanercept Study 314 Investigators. van der Heijde D, et al. Among authors: wajdula js. Ann Rheum Dis. 2006 Dec;65(12):1572-7. doi: 10.1136/ard.2006.056747. Epub 2006 Sep 12. Ann Rheum Dis. 2006. PMID: 16968715 Free PMC article. Clinical Trial.